Hamlet BioPharma Past Earnings Performance
Past criteria checks 0/6
Hamlet BioPharma's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 6% per year.
Key information
-17.0%
Earnings growth rate
-4.9%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -6.0% |
| Return on equity | -79.8% |
| Net Margin | 508,198.3% |
| Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?
Jul 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation
Mar 04We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth
Nov 10We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth
Jun 17Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth
Oct 12Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?
Mar 17Revenue & Expenses Breakdown
How Hamlet BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -43 | 34 | 0 |
| 30 Jun 24 | 0 | -42 | 33 | 0 |
| 31 Mar 24 | 2 | -33 | 29 | 0 |
| 31 Dec 23 | 2 | -27 | 24 | 0 |
| 30 Sep 23 | 2 | -24 | 24 | 0 |
| 30 Jun 23 | 2 | -20 | 22 | 0 |
| 31 Mar 23 | 0 | -25 | 25 | 0 |
| 31 Dec 22 | 1 | -24 | 25 | 0 |
| 30 Sep 22 | 6 | -21 | 27 | 0 |
| 30 Jun 22 | 10 | -17 | 27 | 0 |
| 31 Mar 22 | 13 | -10 | 23 | 0 |
| 31 Dec 21 | 13 | -8 | 21 | 0 |
| 30 Sep 21 | 10 | -8 | 18 | 0 |
| 30 Jun 21 | 9 | -8 | 17 | 0 |
| 31 Mar 21 | 6 | -13 | 20 | 0 |
| 31 Dec 20 | 5 | -17 | 22 | 0 |
| 30 Sep 20 | 3 | -23 | 26 | 0 |
| 30 Jun 20 | 0 | -23 | 24 | 0 |
| 31 Mar 20 | 0 | -24 | 23 | 0 |
| 31 Dec 19 | 0 | -22 | 21 | 0 |
| 30 Sep 19 | 0 | -17 | 17 | 0 |
| 30 Jun 19 | 0 | -17 | 17 | 0 |
| 31 Mar 19 | 0 | -14 | 13 | 0 |
| 31 Dec 18 | 0 | -15 | 15 | 0 |
| 30 Sep 18 | 0 | -15 | 15 | 0 |
| 30 Jun 18 | 0 | -16 | 16 | 0 |
| 31 Mar 18 | 0 | -15 | 15 | 0 |
| 31 Dec 17 | 0 | -17 | 13 | 0 |
| 30 Sep 17 | 0 | -16 | 13 | 0 |
| 30 Jun 17 | 0 | -14 | 11 | 0 |
| 31 Mar 17 | 0 | -13 | 11 | 0 |
| 31 Dec 16 | 0 | -7 | 9 | 0 |
| 30 Sep 16 | 0 | -6 | 7 | 0 |
| 30 Jun 16 | 0 | -5 | 6 | 0 |
| 31 Mar 16 | 0 | -4 | 4 | 0 |
| 31 Dec 15 | 0 | -3 | 3 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -1 | 1 | 0 |
Quality Earnings: HAMLET B is currently unprofitable.
Growing Profit Margin: HAMLET B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HAMLET B is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare HAMLET B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HAMLET B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: HAMLET B has a negative Return on Equity (-79.81%), as it is currently unprofitable.